Sutro Biopharma - STRO Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STRO shares.
View STRO analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month price objectives for Sutro Biopharma's stock. Their STRO share price forecasts range from $15.00 to $21.00. On average, they anticipate the company's stock price to reach $18.67 in the next twelve months. This suggests a possible upside of 151.9% from the stock's current price.
View analysts price targets for STRO or view top-rated stocks among Wall Street analysts.

Sutro Biopharma's stock was trading at $14.88 at the beginning of the year. Since then, STRO shares have decreased by 50.2% and is now trading at $7.41.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our STRO earnings forecast.

Sutro Biopharma, Inc. (NASDAQ:STRO) released its earnings results on Tuesday, November, 8th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.22. The firm earned $25.15 million during the quarter, compared to the consensus estimate of $11.35 million. Sutro Biopharma had a negative net margin of 175.85% and a negative trailing twelve-month return on equity of 53.85%.

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Sutro Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.97%), Vanguard Group Inc. (3.57%), Baillie Gifford & Co. (3.58%), Rubric Capital Management LP (2.44%), Verition Fund Management LLC (2.18%) and State Street Corp (1.44%). Insiders that own company stock include Arturo Md Molina, John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends.

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STRO stock can currently be purchased for approximately $7.41.

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $425.89 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

The company employs 224 workers across the globe.

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.